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Abstract
Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from
the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to
50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be
addressed for quality clinical drug development in ET.
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Introduction
Essential tremor (ET) is the most common tremor disorder and is
characterized by postural and kinetic components.1 It reportedly
occurs in 0.9% of the general population and affects approximately 5%
of adults aged 65 years and older.2 Although ET was considered a
‘‘benign’’ condition in the past, it is now recognized as a progressive
neurological disease, with tremor severity varying widely across
patients.3,4 Tremor amplitude worsens with time, often leading to
difficulties when carrying out activities of daily living, including
writing, drinking, eating, and speaking.5,6
The exact pathophysiology of ET is unknown,4 and developing
effective drugs specifically for ET has been difficult. Drug discovery for
ET has largely depended on clinical observations with medications
that were originally developed to treat other disorders. Only two drugs
have been given Level A ‘‘effective’’ recommendations by the
American Academy of Neurology Practice Parameter, which was
published in 2005 and updated in 2011: the b-adrenergic blocker
propranolol and the anticonvulsant primidone.7 Because approxi-
mately 30–50% of ET patients will not respond adequately to either
primidone or propranolol,8 new therapies for ET are warranted.
This review will describe the methodological issues found in clinical
trials of ET.
Diagnostic criteria
An accurate diagnosis of ET is essential in clinical trials. The
erroneous diagnosis of ET can confound the description of active
treatment response. Estimates suggest that 30–50% of ET cases are
misdiagnosed.9–12 In particular, dystonic tremor, Parkinson’s disease
tremor, and enhanced physiologic tremor are commonly mistaken as
ET. This may be partly explained by similarities in frequency (4–
11 Hz) between these tremor etiologies.13 There are currently no
definitive diagnostic tests or biomarkers for the diagnosis of ET, but
dopamine transporter imaging is helpful in distinguishing ET from
Parkinson’s disease.14 Clinical diagnostic criteria for ET are still the
primary method of diagnosis.
Tremor researchers have developed several sets of diagnostic criteria
to distinguish ET from other forms of tremor. All define ET as a pure
tremor disorder, affecting the upper limbs in nearly all cases, without
signs of dystonia and parkinsonism. The Tremor Research
Investigation Group (TRIG) criteria for definite ET exclude isolated
head tremor and other focal and task-specific tremors, and they
require at least a 5-year history of tremor, so as to reduce the chance of
other tremor disorders.1,4,15,16 The 1996 NIH Collaborative Genetic
Criteria (NIHCGC) include a 0–4 rating of tremor amplitude to
reduce the chance of including enhanced physiologic tremor. Unlike
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the TRIG criteria, the NIHCGC allow the inclusion of coexistent
dystonia in both ‘‘definite’’ and ‘‘probable’’ ET, and Parkinson’s
disease in ‘‘probable’’ ET, as long as a confirmed history of pre-
existing ET is available.17,18 The ET criteria of an ad hoc committee of
the Movement Disorder Society include isolated head tremor if there is
abnormal posturing and do not specify a minimum time for pure
tremor to be present.1 The Washington Heights-Inwood Genetic
Study of Essential Tremor (WHIGET) Scale uses 0–3 or 0–4 ratings of
upper extremity tremor during horizontal extension, pouring, drink-
ing, using a spoon, finger-to-nose testing, and spirography to
distinguish ET from enhanced physiologic tremor.19
Since 1997, nearly all treatment and genetic studies of ET have used
one or more of these sets of diagnostic criteria. All of these diagnostic
schemes are subject to investigator bias and inexperience, and
misdiagnosis is still common.12 Even the definition of ET continues
to be debated, and it is clear that ET is not a specific disease.3
Limitations of published clinical trials
Published clinical trials of ET differ widely with respect to patient
selection, cohort size, type(s) of controls, use of concomitant antitremor
medications, methods and locations of tremor assessment, and
duration of treatment. For example, clinical trials of gabapentin have
produced inconsistent results, depending on whether gabapentin was
used as a monotherapy or as an adjunct therapy.20–23 The mean
(range) number of patients in published ET drug trials is 18.9 (1–208),
and few studies have involved more than one study site.4 Only
topiramate, botulinum toxin, and carisbamate have been studied in
large double-blind placebo-controlled trials. The mean (range)
duration of treatment in published ET drug trials is only 5.4 weeks
(0–120). Prior to 1993, rating scales differed widely among studies, and
none had been validated.6 Accelerometry of postural hand tremor was
common in studies prior to 1993, but postural tremor is a very limited
measure of ET,24 and the results are difficult to compare with rating
scales.4 Finally, many studies did not have suitable controls, and the
ET literature is full of anecdotal reports of efficacy that were not
confirmed in controlled studies.7,25
The intrarater reliability of the Fahn–Tolosa–Marı́n Tremor Rating
Scale is such that a minimum of 15 patients should be adequate in a
double-blind placebo-controlled crossover study design.4 Deuschl et
al.4 recommended that this study design should be used in pilot studies
of promising agents. Positive results should then be confirmed in
placebo-controlled, double-blind multicenter parallel study design,
with a minimum of 60 patients.
Randomization and allocation concealment
Patient bias can be especially difficult to prevent in randomized
controlled studies of treatments, which have side effects that are
common and unique. The blinded assessments in botulinum toxin A
studies of ET are hampered by the common occurrence of muscle
weakness.26,27 Weight loss is common with topiramate, so the large
multicenter trial used raters who were blinded to all other clinical
assessments.28
Deep brain stimulation (DBS) of the ventral intermediate nucleus of
the thalamus has a high magnitude of effect in treating ET, estimated
at 60–90% by various clinical rating scales.7 Sham surgeries have not
been done. Assessments by blinded raters with the stimulator on and
off have been employed, but this does not eliminate patient bias. The
lack of a complete blind makes the true incidence of side effects
difficult to determine.4 Stereotactic targets other than the ventrolateral
thalamus are being explored for ET,4 and future randomized
controlled trials comparing two targets might provide a more reliable
assessment of efficacy and side effects.
Correlating tremor measurement to treatment outcomes
Motion transducers and rating scales have been employed in ET
trials. Accelerometers, gyroscopic transducers, digitizing tablets, and
other motion transducers produce precise measures of tremor
amplitude and frequency. The Fahn–Tolosa–Marin Tremor Rating
Scale (FTM-TRS), the Essential Tremor Rating Assessment Scale
(TETRAS), the WHIGET Scale, and the tremor scale of Bain et al.
have all been validated in patients with ET.
Accelerometers and gyroscopic transducers provide precise but
incomplete measures of body motion in three-dimensional space, and
accelerometers are affected by gravitational artifact.28 Postural tremor
is assessed more completely, but changes in postural tremor may not
be the most valid measure of a treatment effect. For example, a
double-blind placebo-controlled randomized trial of zonisamide found
no significant improvement in the FTM-TRS, but a statistically
significant 40% tremor reduction in postural tremor was measured
with accelerometry.29 Similarly, a double-blind, placebo-controlled,
randomized trial of pregabalin in 22 ET patients yielded significant
improvements in postural tremor measured with accelerometry but no
significant improvement in FTM-TRS scores.30 Insensitivity of the
FTM-TRS to modest changes in tremor severity is one explanation for
these results. It is also possible that postural tremor is more sensitive to
these medications than kinetic tremor, which is usually more disabling.
Clinical ratings of tremor are proportional to the logarithm of
tremor amplitude, measured with a motion transducer, as predicted by
the Weber–Fechner law of psychophysics.31,32 The percentage change
in tremor amplitude T is related to the change in tremor rating (TRS)
according to the following equation, where subscripts 1 and 2 denote




100~ 10a TRS2-TRS1ð Þ{1
h i
100:
The value of a for upper extremity tremor is approximately 0.3–0.5
for a 0–4 (5-point) tremor rating.31 Thus, for a 1-point reduction in a
5-point rating, the percentage reduction in tremor amplitude is 68%,
60%, and 50% for a50.5, 0.4, and 0.3 respectively.
Deuschl et al.4 discussed the lack of a clearly defined minimum
clinically significant effect as a methodologic issue in ET trials. Few
studies have included a global clinical impression of treatment effect
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that can be used to compute the minimum clinically significant change
in rating scale and transducer measures of tremor.4,33,34
Chronic management of ET
There are no long-term randomized controlled studies of any
medication for ET, and the average duration of treatment in published
studies of propranolol and primidone is less than 1 month.4 Future
studies should address the long-term benefit of drugs for ET. Studies
assessing the long-term efficacy of propranolol and primidone up to a
year after initial treatment have yielded positive results on the control
of tremor.8,35–37 However, it is now clear that these medications may
lose efficacy over time, requiring higher doses to achieve their
tremorolytic effect, and may cause side effects with both acute and
chronic use.8,35,36,38 Up to 50% of ET patients will not respond to
primidone or propranolol.8
Assessing the impact of therapy on quality of life
It is not uncommon for patients with ET to be forced into an early
retirement, a result of the increasing impact of disease progression on
their ability to lead a self-sufficient life.39 Assessments of the patient’s
quality of life become paramount in the clinical evaluation of therapeutic
efficacy. Ferrara et al.40 recently included quality of life as an outcome
measure in a trial of pregabalin for ET. Quality of life should be assessed
for all ET treatments, given their side effects, cost, and modest benefit.
Although the SF-36 scale for assessing quality of life is valid and
widely used,41 the Questionnaire for Essential Tremor (QUEST) is a
newer, more specific assessment of quality of life changes associated
with ET. Developed in 2005 by Tröster et al.,42 QUEST was designed
as a clinical tool for correlating changes in 30 aspects of tremor
severity, social and personal disability, and perception of health. An
independent validation study of the QUEST performed by Martinez-
Martin et al.43 concluded that most of the psychometric parameters
were found to be satisfactory in their ability to assess the impact of ET
on the patients’ quality of life. The use of QUEST in clinical trials will
give clinicians important information for estimating the clinical
relevance of a response to therapy.
Conclusion
Thus far, clinical trials in ET have provided information to patients
and clinicians alike regarding management of this debilitating disorder.
While propranolol and primidone provide symptomatic relief to a
substantial number of ET patients, up to half of those afflicted do not
receive clinically significant benefit from these drugs; this is a clear sign
that ET-specific medications are needed. As the ongoing efforts toward
understanding the pathophysiology of ET continue, investigators will
hopefully open a new chapter in the pharmaceutical development of
more effective ET treatments.
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